Letter to the EditorHepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment
Section snippets
Conflict of interest
Harrys A. Torres is or has been the principal investigator for studies funded by Gilead Sciences, Merck & Co., Inc., and Vertex Pharmaceuticals, with all funds paid to The University of Texas MD Anderson Cancer Center. He also is or has been a paid scientific advisor for Gilead Sciences, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Vertex Pharmaceuticals, Genentech, Novartis, Astellas Pharma, Pfizer Inc., and Theravance Biopharma, Inc. The terms of these arrangements are managed by MD
Acknowledgements
We thank Don Norwood for editorial assistance.
References (6)
- et al.
Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution
J Hepatol
(2016) - et al.
Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents
Biol Blood Marrow Transplant
(2016) - et al.
Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population
J Natl Compr Canc Netw
(2015)
There are more references available in the full text version of this article.
Cited by (0)
© 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.